Abstract
Albuminuria is a cardiovascular and renal risk factor in patients with diabetes, patients with hypertension, and the general population. Risk has been shown to increase continuously with increasing urinary albumin levels, starting at levels that once were considered normal. This association is maintained even after adjusting for numerous other factors. Studies also established that a decrease in albuminuria leads to improvement in both cardiovascular and renal outcomes. These data suggest that urinary albumin should be measured routinely and treated to afford cardiovascular and renoprotection.
MeSH terms
-
Albumins
-
Albuminuria / diagnosis*
-
Albuminuria / drug therapy*
-
Albuminuria / physiopathology
-
Albuminuria / urine
-
Angiotensin II Type 1 Receptor Blockers / pharmacology
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Blood Pressure / drug effects
-
Blood Pressure / physiology
-
Diabetes Complications / diagnosis
-
Diabetes Complications / drug therapy
-
Diabetes Complications / prevention & control
-
Diabetes Complications / urine
-
Diabetes Mellitus / physiopathology
-
Diabetes Mellitus / urine*
-
Diabetic Angiopathies / diagnosis
-
Diabetic Angiopathies / drug therapy
-
Diabetic Angiopathies / prevention & control*
-
Diabetic Angiopathies / urine
-
Diabetic Nephropathies / diagnosis
-
Diabetic Nephropathies / drug therapy
-
Diabetic Nephropathies / prevention & control*
-
Diabetic Nephropathies / urine
-
Disease Progression
-
Drug Therapy, Combination
-
Humans
-
Hypertension / drug therapy
-
Hypertension / physiopathology
-
Kidney Failure, Chronic / diagnosis
-
Kidney Failure, Chronic / prevention & control
-
Kidney Failure, Chronic / urine
-
Predictive Value of Tests
-
Prognosis
-
Risk Factors
-
Treatment Outcome
Substances
-
Albumins
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors